In the present study, the FRF group had a lower Hb drop (anaemia and bleeding management), less pain (regional or local analgesia), better functional outcomes (early mobilisation), and fewer complications (morbidity), consistent with the results of previous studies. This evidence concerns the gene GSTM1 and anemia.